VERACYTE
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis are available to patients, and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide.
VERACYTE
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2006-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.veracyte.com
Total Employee:
501+
Status:
Active
Contact:
6502436301
Email Addresses:
[email protected]
Total Funding:
1.1 B USD
Technology used in webpage:
Domain Not Resolving Amazon Mobile Non Scaleable Content IPv6 ReCAPTCHA Organization Schema Wordpress Plugins U.S. Server Location CrUX Top 50m Common Name Invalid
Similar Organizations
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
LightDeck Diagnostics
LightDeck is a developer of on-the-spot diagnostic products used to offer fast, accurate, simple, and low-cost diagnostic tests.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Radius Health
Radius Health develops drug therapies for osteoporosis and women’s health.
Tandem Diabetes Care
Tandem diabetes care provides products that empower both people with diabetes and those who care for them.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-01-08 | C2i Genomics | C2i Genomics acquired by Veracyte | 70 M USD |
| 2021-06-01 | HalioDx | HalioDx acquired by Veracyte | 260 M EUR |
| 2021-02-03 | Decipher Biosciences | Decipher Biosciences acquired by Veracyte | 600 M USD |
| 2014-09-04 | Allegro Diagnostics | Allegro Diagnostics acquired by Veracyte | 21 M USD |
Investors List
Visium Healthcare Partners
Visium Healthcare Partners investment in Post-IPO Debt - Veracyte
Armentum Partners
Armentum Partners investment in Debt Financing - Veracyte
Domain Associates
Domain Associates investment in Series C - Veracyte
GE Ventures
GE Ventures investment in Series C - Veracyte
TPG Biotech
TPG Biotech investment in Series C - Veracyte
Versant Ventures
Versant Ventures investment in Series C - Veracyte
Kleiner Perkins
Kleiner Perkins investment in Series C - Veracyte
Kleiner Perkins
Kleiner Perkins investment in Venture Round - Veracyte
Domain Associates
Domain Associates investment in Venture Round - Veracyte
Versant Ventures
Versant Ventures investment in Series B - Veracyte
Newest Events participated
Participated in 3rd World Congress on Thyroid Cancer
on 2017-07-27 as exhibitor
Participated in 3rd World Congress on Thyroid Cancer
on 2017-07-27 as sponsor
Key Employee Changes
| Date | New article |
|---|---|
| 2023-09-27 | Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer |
| 2022-02-22 | Veracyte Appoints Jonathan Wygant as Chief Accounting Officer |
Official Site Inspections
http://www.veracyte.com Semrush global rank: 1.4 M Semrush visits lastest month: 18.2 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Veracyte"
Who we are - Veracyte
Feb 3, 2022 About Veracyte. Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. We …See details»
Leadership - Veracyte
Veracyte’s executive team members leverage their diverse expertise in life sciences and diagnostics to deliver transformational solutions for physicians and patients. Board of directors. …See details»
Veracyte - Crunchbase Company Profile & Funding
Organization. Veracyte . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Veracyte is a …See details»
Veracyte, Inc. | Investor Relations
Mar 11, 2025 Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to …See details»
Governance overview - Veracyte, Inc.
Veracyte is committed to promoting ethical practices throughout our organization. Find key governance documents and committee charters. Skip to main navigation Veracyte, Inc. …See details»
Org Chart Veracyte - The Official Board
Organizational Chart of Veracyte. Veracyte www.veracyte.com. has 25 executives and 1 subsidiary +1 650 243 6350; Add an executive. Veracyte (VCYT) News . Anything missing? …See details»
Veracyte, Canada - LifeScienceHistory.com
Veracyte, Canada www.veracyte.com. 1120 Hamilton St, Unit 201. Vancouver, BC V6B 2S2. Company Info Phone (650) 243-6300 Year Established 2008 Ticker VCYT Exchange …See details»
Veracyte, Inc. (VCYT) Company Profile & Facts - Yahoo Finance
Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California. Corporate Governance Veracyte, Inc.’s ISS Governance QualityScore as of April 1, 2025 is 5.See details»
Veracyte Company Profile - Office Locations, Competitors ... - Craft
Oct 28, 2024 Veracyte has 5 employees across 5 locations and $445.76 m in annual revenue in FY 2024. See insights on Veracyte including office locations, competitors, revenue, financials, …See details»
Veracyte, Inc. Company Profile - Dun & Bradstreet
Company Description: Veracyte is a global genomic diagnostics company that aims to improve patient care through better diagnosis and treatment decisions for patients with cancer and …See details»
Veracyte Company Profile | Management and Employees List
Veracyte Profile and History. Founded in 2006, Veracyte is emerging in the field of molecular cytology by developing molecular tests designed to improve the diagnostic accuracy of …See details»
Veracyte - Funding, Financials, Valuation & Investors - Crunchbase
Veracyte is registered under the ticker NASDAQ:VCYT . Their stock opened with $13.00 in its Oct 30, 2013 IPO. Veracyte is funded by 7 investors. Visium Healthcare Partners and Armentum …See details»
Veracyte (VCYT) Company Profile & Description - Stock Analysis
Oct 30, 2013 Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous …See details»
Veracyte, Inc. | Veracyte Announces First Quarter 2025 Financial …
Mar 31, 2025 Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18%. Conference call and webcast today at 4:30 p.m. ET. SOUTH SAN …See details»
Working at Veracyte
Veracyte’s commitment to improving patient care is unwavering and would not be possible without our world-class team. We are a global organization united by our mission to address unmet …See details»
Veracyte - 2025 Company Profile, Funding & Competitors - Tracxn
Apr 29, 2025 Veracyte is a public company based in San Francisco (United States), founded in 2008 by Bonnie Anderson. It operates as a Developer of genomics-based diagnostics for …See details»
Veracyte - Overview, News & Similar companies | ZoomInfo.com
Veracyte contact info: Phone number: (650) 243-6300 Website: www.veracyte.com What does Veracyte do? Founded in 2006, Veracyte is emerging in the field of molecular cytology by …See details»
Veracyte Inc Company Profile - Overview - GlobalData
Veracyte Inc (Veracyte) is a diagnostics company that uses genomic technology to resolve diagnostic ambiguity. the company offers products such as Afirma, Percepta, Envisia, …See details»
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What …
9 hours ago Following the latest results, Veracyte's eleven analysts are now forecasting revenues of US$492.7m in 2025. This would be a reasonable 6.3% improvement in revenue …See details»
Veracyte, Inc. | Veracyte Announces Fourth Quarter and Full-Year …
Dec 31, 2021 Veracyte is initiating 2022 annual total revenue guidance of $260 million to $275 million, representing year-over-year growth of 18% to 25%, compared to the prior year. …See details»